A phase ib trial to evaluate the safety and efficacy of quinacrine plus capecitabine in patients with refractory metastatic colorectal cancer.

Arthur Winer,Namrata Vijayvergia,Steven J. Cohen,Crystal S. Denlinger,Igor Astsaturov,Efrat Dotan,Jean-Nicolas Gallant,Edward Wenge Wang,Miriam Kunkel,Bora Lim,Harold A. Harvey,Jeffrey Sivik,Lanlan Zhou,Kenneth Korzekwa,Karen Ruth,Eric A. Ross,Wafik El-Deiry

A phase ib trial to evaluate the safety and efficacy of quinacrine plus capecitabine in patients with refractory metastatic colorectal cancer.

2019

Arthur Winer
Namrata Vijayvergia
Steven J. Cohen
Crystal S. Denlinger
Igor Astsaturov
Efrat Dotan
Jean-Nicolas Gallant
Edward Wenge Wang
Miriam Kunkel
Bora Lim
Harold A. Harvey
Jeffrey Sivik
Lanlan Zhou
Kenneth Korzekwa
Karen Ruth
Eric A. Ross
Wafik El-Deiry

e15020Background: Acridines emerged from a cell-based screen for p53-pathway restoring compounds. Quinacrine, an acridine demonstrating p53 pathway restoration properties, displayed preclinical ant...

Keywords:

Refractory
Capecitabine
Colorectal cancer
Oncology
Pathology
Medicine
Internal medicine
Acridine
in patient
P53 pathway
Cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations